HC Wainwright reissued their buy rating on shares of Oragenics (NYSEAMERICAN:OGEN) in a research note issued to investors on Tuesday morning, AnalystRatings.com reports. HC Wainwright currently has a $2.00 price objective on the biotechnology company’s stock.
NYSEAMERICAN:OGEN opened at $0.57 on Tuesday. Oragenics has a one year low of $0.35 and a one year high of $1.44.
An institutional investor recently raised its position in Oragenics stock. Barclays PLC grew its position in Oragenics Inc (NYSEAMERICAN:OGEN) by 49.9% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 300,400 shares of the biotechnology company’s stock after buying an additional 100,000 shares during the period. Barclays PLC owned 0.65% of Oragenics worth $162,000 at the end of the most recent quarter.
Oragenics, Inc develops novel antibiotics against infectious diseases and treatments for oral mucositis. It is developing OG716, an antibiotic product candidate, which is in nonclinical testing for healthcare-associated infections, as well as other homolog antibiotic product candidates. The company is also developing AG013, which is in Phase II clinical trial for the treatment of oral mucositis in cancer patients.
Further Reading: Hang Seng Index (HSI)
Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.